CONTACT INFORMATIONBIOGRAPHYCREDENTIALSAWARDSCLINICAL TRIALSDaniel L. Mulkerin, M.D.Contact InformationPhone NumbersAppointment: (585) 276-3000A member of the University of Rochester Medical Faculty GroupgroupAn Accountable Health PartnerassignmentAccepting New PatientsLocationsUniversity of Rochester Medical CenterSchool of Medicine and Dentistry601 Elmwood Ave, Box 704Rochester, NY 14642Faculty AppointmentsProfessor - Department of Medicine , Hematology/Oncology (SMD) Professor - Cancer Center - JointPatient Care SettingCancerBiographyProfessional BackgroundDr. Mulkerin's clinical practice is focused on gastrointestinal malignancies. He is actively involved in clinical research. He is a highly respected mentor and has extensive teaching experience. Dr. Mulkerin holds an important role in enhancing and advancing the Department of Medicine's footprint in our region.CredentialsEducation1992MD | Thomas Jefferson University Hospital (USA)Post-doctoral Training & Residency07/01/1996 - 06/30/1999Fellowship in Medical Oncology at University of Wisconsin Hospital and Clinics06/25/1993 - 06/30/1996Residency in Internal Medicine at University of Wisconsin Hospital and Clinics06/24/1992 - 06/24/1993Internship in Internal Medicine at University of Wisconsin Hospital and ClinicsVIEW ALL expand_moreAwards2017 - 2018Award for Service/Leadership Excellence2016UW Health Patient Experience Physician Champion Award2015UW Health Physician Excellence Regional Services Award2014UW Health Patient Experience Physician Champion Award2013 - 2021Top Doctor's in America2006Top Doctors: Madison Magazine1992Hobart Armory Hare Honor SocietyLocation: Jefferson Medical CollegeUW Hematology/Oncology Division/Department of MedicineVIEW ALL expand_moreClinical TrialsAn Open-label Phase 1 Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaLead Researcher: Daniel L Mulkerin The main purpose of this research study is to determine the maximum tolerable dose (MTD) of SX-682 in combination with nivolumab in patients with metastatic pancreatic ductal adenocarcinoma who have completed at least 16 weeks of first line chemotherapy treatment without evidence of disease progression. View Study Details A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic CancerLead Researcher: Daniel L Mulkerin This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly). View Study Details Close WindowSchedule an appointment with Daniel L. Mulkerin, M.D.Please answer the following questions to help us find the right appointment for you.Important: If you believe that you have a medical or psychiatric emergency, please call 911 or go to the nearest hospital. This website is not intended for emergency care.Have you seen this provider in the last 2 years?YesNoExisting Patient Schedule or request a follow up appointment online through MyChart. If you do not have a MyChart account, please close this window and call the appointment phone number. Daniel L. Mulkerin, M.D. is currently scheduling for the following appointment type(s): Our policy does not permit patients to establish care with multiple providers within the same practice or specialty without prior approval. If you choose a new provider in the same office, we will cancel the appointment. Please contact the office directly with questions on this policy.